Valid Ghana · FDA Ghana

MONASAN INJECTION (Each ampoule contains Pluphenare Decanoate 2mg

Pluphenare Decanoate

FDA/SD.265-020188 Pluphenare Decanoate 2mg

What it does

Pluphenare is a medication used to treat various conditions.

Commonly used for: psychosis (mental health conditions), schizophrenia, severe anxiety, bipolar disorder …

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Medicine sourcing is available in Kenya only. We don't sell or dispense medicines - licensed pharmacies do.

Sourcing - Kenya only

Registration & product details

Registration no.
FDA/SD.265-020188
Registration date
2026-02-24
Expiry date
2030-12-01
Status
Valid
Active ingredient
Pluphenare Decanoate
Dosage form
Pluphenare Decanoate
Strength
2mg
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Duopharma
Country of origin
-
Manufacturer location
Lot 2599, Jalan Seruling 59, Kawasan 3, Taman Klang Jaya, 41200 Klang, Selangor, Malaysia

Source: Food and Drugs Authority · fetched 2026-05-22 02:34:47 · updated 2026-10-20 04:00:09

Disclaimer: This information is sourced from Food and Drugs Authority (Ghana). Always consult a qualified healthcare professional before using any medication.

About this medicine

Pluphenare is a medication used to treat various conditions.

What it treats

  • psychosis (mental health conditions)
  • schizophrenia
  • severe anxiety
  • bipolar disorder
  • nausea and vomiting

How it works

Pluphenare helps to balance certain chemicals in the brain, which can improve mood and reduce symptoms of mental health disorders.

Who it's for

This medication is for adults and children experiencing severe mental health issues or significant nausea.

Cautions

  • • May cause drowsiness; avoid driving or operating heavy machinery until you know how it affects you.
  • • Not suitable for people with certain heart conditions or severe liver problems.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: pluphenare

Pluphenare is an antipsychotic medication that is primarily used to manage various mental health disorders. It is part of the phenothiazine class and is known for its effectiveness in treating symptoms of schizophrenia and other psychotic disorders. This drug works by modulating neurotransmitter activity in the brain, particularly dopamine. Due to its pharmacological properties, it can also be used to manage severe behavioral problems and agitation in certain patient populations.

Indications

  • Schizophrenia
  • Schizoaffective disorder
  • Severe behavioral problems
  • Agitation in psychiatric patients
  • Acute mania in bipolar disorder

Dosage

Children: Refer to specific dosing guidelines in the appropriate paediatric pharmacology reference.

Adults: Refer to specific dosing guidelines in the appropriate pharmacological reference.

Mechanism of action

Pluphenare exerts its effects mainly by antagonizing dopamine receptors, particularly the D2 subtype. This blockade leads to a reduction in dopaminergic transmission in the central nervous system, which is believed to contribute to its antipsychotic effects. Additionally, Pluphenare may also block other neurotransmitter receptors, including serotonin receptors, which can further aid in modulating mood and behavior.

Pharmacodynamics

The pharmacodynamic profile of Pluphenare involves its ability to stabilize mood and reduce psychotic symptoms. By antagonizing dopamine receptors, it decreases dopaminergic hyperactivity, which is often associated with conditions such as schizophrenia. The drug may also exhibit sedative properties due to its action on histamine and alpha-adrenergic receptors, which can help alleviate agitation and anxiety in patients.

Pharmacokinetics

Pluphenare is absorbed relatively well from the gastrointestinal tract, with peak plasma concentrations typically occurring within several hours post-administration. It is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, and has a long half-life, allowing for once-daily dosing in many cases. The drug is excreted mainly in the urine, with a significant portion eliminated as metabolites. Its pharmacokinetic profile can be influenced by factors such as age, liver function, and concurrent medications.

Pregnancy

Consult with a healthcare provider as safety has not been established.

Breast-feeding

Consult with a healthcare provider as safety has not been established.

Storage

Store in a cool, dry place away from direct sunlight.

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.